Linde plc (LIN)
NASDAQMaterialsChemicals - SpecialtySnapshot 2026-09-14
$464.41-0.39%
Close 2026-09-14 · 1-day change
NASDAQMaterialsChemicals - SpecialtySnapshot 2026-09-14
Research Workspace
Put LIN beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Materials: fringe margins under pressure (0q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is growing steadily — about 7% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, guidance credibility.
View ManagementExpectations look high — the market is pricing in about 20% growth a year, above the roughly 6% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskLIN's growth in the industrial gases sector relies on its ability to maintain strong margins and capitalize on recent investments. Revenue grew 9% year over year, and the latest earnings report was inline with expectations. It trades at 27× P/E, above the 18× peer median, indicating that the market is pricing in more growth than forecasted. If LIN cuts guidance on the next call, that could negatively impact its stock. Peer multiples imply a price about 19% below where it trades, suggesting it looks expensive on this basis. Our read remains intact.
Trailing returns as of 2026-09-14. LIN is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 28 analysts currently covering LIN (as of Sep 2026).
Based on 7 Wall Street analysts offering 12-month price targets for LIN in the last 4 months.
Continue this research
Compare LIN with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| LIN Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 14 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Materials (broad) — fair value, gap to price, and forward P/E.
Compare the value case
Put LIN next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Support growth with capital expenditures of $5.5B to $6.0B in 2026
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
Current $464.41
The last 12 months of price, then the range of analyst 12-month targets from today’s $464.41.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Higher CAPEX limits growth potential and capital allocation.
Healthcare unit challenges may hinder overall growth objectives.
Advances: Support growth with capital expenditures of $5.5B to $6.0B in 2026
Investment supports growth in electronics market.
Advances: Achieve Q2 EPS growth of 8% to 10%
Earnings call confirms EPS growth target for Q2.
Threatens: Achieve Q2 EPS growth of 8% to 10%
Q2 EPS growth missed expectations despite beating estimates.
Potential legal issues could impact financial performance.
Lawsuit could impact financial performance and growth objectives.
Space propellant growth aligns with management's growth objectives.
